Influence of isoprinosine on lymphocyte function in virus-infected feeder pigs.
Pseudorabies is a porcine herpesvirus of major importance in the swine industry. Isoprinosine is an immunomodulating drug that has been shown to be beneficial in treating herpesvirus infections. Twenty-four 7-week-old pigs were allotted within litters to 1 of 4 groups: control, isoprinosine (ISO), pseudorabies virus (PRV), or isoprinosine and pseudorabies virus (ISO-PRV). Isoprinosine was administered daily for 16 days to the ISO and ISO-PRV groups (75 mg/kg of body weight/day, PO). Immunity in pigs in the PRV and ISO-PRV groups was challenged with pseudorabies virus (10(5) TCID50 units) on day 4. Rectal temperatures and viral excretion were monitored daily; total and differential leukocyte counts, lymphocyte response to mitogens, and interleukin-2 production were monitored every 4 days. Pigs challenge-inoculated with pseudorabies virus became ill, with the ISO-PRV group most severely affected. Rectal temperatures were high (P less than 0.05) in virally challenged pigs on days 5 to 12 and 14 to 16; isoprinosine did not alter this effect. Pseudorabies virus-infected pigs had leukocytosis (P less than 0.05) on days 12 and 16, primarily caused by neutrophilia. Concanavalin A-stimulated lymphocyte proliferation was decreased (P less than 0.06) in both PRV and ISO-PRV groups on day 12, compared with control pigs, but only in the PRV group on day 16. Pokeweed mitogen-stimulated lymphocyte proliferation was decreased (P less than 0.02) in ISO-PRV pigs on day 8 of the experiment. Interleukin-2 concentrations, pooled over all sampling days, were decreased (P less than 0.03) in pseudorabies virus-infected pigs. Viral excretion was not altered by isoprinosine treatment. These data suggest that pseudorabies virus infection decreased lymphocyte proliferative responses and interleukin-2 production in pigs, and that isoprinosine did not mitigate these effects.
Flaming
K P
KP
Department of Anatomy, College of Veterinary Medicine, Kansas State University, Manhattan 66506.
Blecha
F
F
Fedorka-Cray
P J
PJ
Anderson
G A
GA
D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects; D007288:Inosine; D007542:Inosine Pranobex / Q000494:pharmacology* / Q000627:therapeutic use; D007376:Interleukin-2 / Q000096:biosynthesis; D007958:Leukocyte Count / Q000187:drug effects / Q000662:veterinary; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D009296:Nasal Cavity / Q000382:microbiology; D009500:Neutralization Tests; D011557:Pseudorabies / Q000188:drug therapy / Q000276:immunology*; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy / Q000276:immunology*
D007376:Interleukin-2; D007288:Inosine; D007542:Inosine Pranobex